Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space
Terumo Medical Corporation (TRUMY) recently unveiled its AZUR HydroPack Peripheral Coil System in the United States. This marks significant progress in terms of the company's global presence as a leading player in embolotherapy solutions.
The coil system boasts a soft, universal-shaped platinum and hydrogel composition, which distinguishes it prominently in the peripheral coil market.
Advanced Hydrogel Technology
The AZUR HydroPack’s hydrogel technology creates a gel core that promotes new tissue growth, a departure from traditional platinum coils. This unique feature enhances efficiency and minimizes reperfusion, thus advancing patient outcomes.
According to Terumo, the coil's versatility and efficiency provide interventional radiologists and vascular surgeons with an ideal solution for diverse peripheral embolization procedures. With a .018" primary wind and lengths ranging from 5 to 60 cm, it is currently the longest gel core on the market, offering flexible sizing options. According to the company, the soft coil design paired with an enhanced pusher enables ease of delivery, optimized trackability and microcatheter stability.
Image Source: Zacks Investment Research
A Superior Solution
As the market for peripheral coil embolization expands, Terumo's AZUR HydroPack stands out with its advanced design and compatibility with microcatheters. The absence of vessel-diameter sizing requirements, except for the placement of an anchor coil, reduces inventory needs.
The AZUR HydroPack complements Terumo's embolotherapy portfolio, seamlessly fitting in with the AZUR CX Peripheral Coil System and AZUR Framing Coil System.
Market Prospects
Going by a report from Exactitude Consultancy, the embolotherapy market size is set to witness a CAGR of 8.1% from 2023 to 2030. As chronic diseases are becoming more prevalent, the market is expanding, driven by increased incidences of liver cancer and hepatocellular carcinoma. Factors such as the demand for minimally invasive procedures, higher disposable incomes and advanced technological breakthroughs contribute to market growth.
Share Price Performance
Shares of TRUMY have risen 10% in the past year against the industry’s 7.4% decline.
Zacks Rank and Key Picks
Terumo carries a Zacks Rank #4 (Sell) currently.
Some better-ranked stocks in the broader medical space are Insulet (PODD), Haemonetics (HAE) and DexCom (DXCM). While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
Terumo Corp. (TRUMY) : Free Stock Analysis Report
